-
Sun Pharma to Invest Rs 240 Crore in Halol Plant for New Products
Sun Pharmaceutical Industries Ltd. (Sun Pharma) has announced that it will invest Rs 240 crore to expand its Halol manufacturing facility in Gujarat. The expansion project will be used to manufacture new products and increase production capacity.
-
Sun Pharma's Ranbaxy Arm to Acquire US Generics Drugmaker Concert Pharmaceuticals for $576 Million
Sun Pharmaceutical Industries Ltd.'s subsidiary, Ranbaxy Laboratories Ltd., has entered into an agreement to acquire Concert Pharmaceuticals, Inc., a US-based specialty pharmaceutical company, for approximately $576 million in cash.
-
Sun Pharma Q3 Net Profit Rises 8.3% to Rs 2,341 Crore
Sun Pharmaceutical Industries Ltd. (Sun Pharma) on Thursday reported a consolidated net profit of Rs 2,341.22 crore for the third quarter ended December 2022, a growth of 8.3 per cent compared to Rs 2,161.87 crore in the same period last year.
-
Sun Pharma receives USFDA nod for generic Nexavar
The drug is used for treating advanced liver cancer and advanced kidney cancer. The generic version of Nexavar is...
-
Sun Pharma Q3 net profit rises 36%
Sun Pharmaceutical Industries Ltd on Friday reported a 36% year-on-year rise in its consolidated net profit to Rs...
-
Sun Pharma gets USFDA nod for generic cancer drug
Sun Pharmaceutical Industries on Tuesday said it has received final approval from the US health regulator for its...
-
Sun Pharma Receives US FDA Approval for Generic Version of VESIcare Tablets
Sun Pharmaceutical Industries Ltd. (Sun Pharma) has received final approval from the United States Food and Drug Administration (US FDA) for Solifenacin Succinate Tablets, 5 mg and 10 mg, the generic version of VESIcare Tablets, 5 mg and 10 mg, of Astellas Pharma US, Inc.
-
Sun Pharma Launches Biosimilar Pegfilgrastim in Japan
Sun Pharmaceutical Industries Ltd. (Sun Pharma) has announced the launch of its biosimilar Pegfilgrastim, under the brand name Pelgrapro, in Japan. Pelgrapro is a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor (G-CSF) used to prevent neutropenia in patients undergoing chemotherapy.
-
Sun Pharma's Ilumya Approved in the EU for Treatment of Plaque Psoriasis
Sun Pharmaceutical Industries Ltd. (Sun Pharma) has announced that the European Commission has granted marketing authorization for Ilumya (tildrakizumab) for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.
-
Sun Pharma's India Business Posts Robust Growth in Q4
The company's India business grew by 21.7% to INR 3,317 crore in Q4.
-
Sun Pharma Receives US FDA Approval for Generic Valcyte Tablets
The approval allows Sun Pharma to market and distribute its generic version of Valcyte tablets in the US market.
-
Sun Pharma Collaborates with GSK to Develop and Commercialize Anti-Infective Drugs
The collaboration will focus on the development and commercialization of innovative anti-infective drugs for serious bacterial infections.
-
Sun Pharma's Subsidiary Taro Pharmaceuticals Announces Acquisition of Dermavant Sciences
The acquisition will expand Taro's dermatology portfolio and strengthen its position in the US market.
-
Sun Pharma Launches New Biosimilar Drug for Advanced Colorectal Cancer
The launch of the biosimilar drug provides a more affordable treatment option for patients with advanced colorectal cancer in India.
-
Sun Pharma Launches Generic Version of Xeljanz in the US
Sun Pharmaceutical Industries Ltd. (Sun Pharma) has launched a generic version of Xeljanz (tofacitinib citrate) in the United States. Tofacitinib is a prescription medicine used to treat adults with moderately to severely active rheumatoid arthritis (RA).
-
Sun Pharma Receives USFDA Approval for Generic Version of Amjevita
Sun Pharmaceutical Industries Ltd. (Sun Pharma) has received approval from the United States Food and Drug Administration (USFDA) for its generic version of Amjevita (adalimumab-atto), a biosimilar to Humira.
-
Sun Pharma Partners with Evotec to Develop Novel Therapies for Immuno-Oncology
Sun Pharmaceutical Industries Ltd. (Sun Pharma) has entered into a strategic partnership with Evotec SE to develop novel therapies for immuno-oncology. The partnership will leverage Evotec's expertise in drug discovery and Sun Pharma's capabilities in clinical development and commercialization.
-
Sun Pharma Acquires Concert Pharmaceuticals for $576 Million
Sun Pharmaceutical Industries Ltd. has acquired Concert Pharmaceuticals, Inc., a biotechnology company focused on the development and commercialization of medicines for rare diseases, for approximately $576 million.
-
Sun Pharma's Ilumya Approved for Plaque Psoriasis in Europe
The European Commission has approved Sun Pharmaceutical Industries Ltd.'s Ilumya (tildrakizumab) for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.
-
Sun Pharma Partners with Alnylam to Develop and Commercialize RNAi Therapeutics
Sun Pharmaceutical Industries Ltd. and Alnylam Pharmaceuticals, Inc. have entered into a strategic collaboration to develop and commercialize RNA interference (RNAi) therapeutics for rare diseases.
-
Sun Pharma Q3 Net Profit Jumps 33% to Rs 2,523 Crore
Sun Pharmaceutical Industries Ltd. reported a 33% increase in its net profit to Rs 2,523 crore for the quarter ended December 2022, driven by strong growth in its specialty and emerging markets businesses.
-
Sun Pharma Launches Generic Version of Copaxone in the US
Sun Pharmaceutical Industries Ltd. has launched a generic version of Copaxone (glatiramer acetate injection) in the United States, indicated for the treatment of relapsing forms of multiple sclerosis.
-
Sun Pharma launches generic version of blockbuster cancer drug
Sun Pharmaceutical Industries Ltd has launched a generic version of a blockbuster cancer drug in the United States, the company said on Tuesday.
-
Sun Pharma acquires Concert Pharmaceuticals for $576 million
Sun Pharmaceutical Industries Ltd has acquired Concert Pharmaceuticals for $576 million in an all-cash transaction.
-
Sun Pharma partners with Biocon to develop and commercialize biosimilar drugs
Sun Pharmaceutical Industries Ltd has entered into a partnership with Biocon to develop and commercialize biosimilar drugs.